BRPI0416358A - inibidores de citocina à base de pirazolona bicìclica - Google Patents

inibidores de citocina à base de pirazolona bicìclica

Info

Publication number
BRPI0416358A
BRPI0416358A BRPI0416358-3A BRPI0416358A BRPI0416358A BR PI0416358 A BRPI0416358 A BR PI0416358A BR PI0416358 A BRPI0416358 A BR PI0416358A BR PI0416358 A BRPI0416358 A BR PI0416358A
Authority
BR
Brazil
Prior art keywords
pyrazol
cytokine inhibitors
based cytokine
dihydro
ones
Prior art date
Application number
BRPI0416358-3A
Other languages
English (en)
Inventor
Michael Philip Clark
Steven Karl Laughlin
Adam Golebiowski
Todd Andrew Brugel
Mark Sabat
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0416358A publication Critical patent/BRPI0416358A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

INIBIDORES DE CITOCINA à BASE DE PIRAZOLONA BICìCLICA. A presente invenção refere-se a 6,7-dihidro-5H-pirazol¢1,2a! pirazol-1-onas que inibem a liberação extracelular de citocinas inflamatórias, sendo as ditas citocinas responsáveis por um ou mais estados doentios em seres humanos ou mamíferos superiores. A presente invenção refere-se, também, a composições que contêm as ditas 6,7-dihidro-5H-pirazol¢1,2a! pirazol-1-onas e aos métodos para evitar, minorar ou, de outro modo, controlar a liberação de enzimas que, conforme se entende, são os componentes ativos responsáveis pelos estados doentios descritos aqui.
BRPI0416358-3A 2003-11-10 2004-11-09 inibidores de citocina à base de pirazolona bicìclica BRPI0416358A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51888603P 2003-11-10 2003-11-10
PCT/US2004/037264 WO2005047287A2 (en) 2003-11-10 2004-11-09 Bicyclic pyrazolone cytokine inhibitors

Publications (1)

Publication Number Publication Date
BRPI0416358A true BRPI0416358A (pt) 2007-05-08

Family

ID=34590314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416358-3A BRPI0416358A (pt) 2003-11-10 2004-11-09 inibidores de citocina à base de pirazolona bicìclica

Country Status (18)

Country Link
US (2) US7482356B2 (pt)
EP (1) EP1682551A2 (pt)
JP (1) JP2007510739A (pt)
KR (1) KR100835152B1 (pt)
CN (1) CN1878772A (pt)
AR (1) AR046618A1 (pt)
AU (1) AU2004289691B2 (pt)
BR (1) BRPI0416358A (pt)
CA (1) CA2545781A1 (pt)
IL (1) IL175151A0 (pt)
MA (1) MA28154A1 (pt)
NO (1) NO20062639L (pt)
PE (1) PE20050578A1 (pt)
RU (1) RU2358976C2 (pt)
SG (1) SG147476A1 (pt)
TW (1) TW200518754A (pt)
WO (1) WO2005047287A2 (pt)
ZA (1) ZA200603582B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101182114B1 (ko) * 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
CN115286635B (zh) * 2022-08-22 2023-10-24 河南师范大学 一种手性并环吡唑啉酮类化合物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124982A (en) 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529154A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
US6849627B2 (en) * 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en) * 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US6566357B1 (en) * 2001-09-20 2003-05-20 The Procter & Gamble Co. Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6677337B2 (en) 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines

Also Published As

Publication number Publication date
US20090069355A1 (en) 2009-03-12
SG147476A1 (en) 2008-11-28
AU2004289691B2 (en) 2009-04-23
WO2005047287A2 (en) 2005-05-26
ZA200603582B (en) 2007-04-25
AU2004289691A1 (en) 2005-05-26
AR046618A1 (es) 2005-12-14
TW200518754A (en) 2005-06-16
CA2545781A1 (en) 2005-05-26
RU2006114580A (ru) 2007-12-20
RU2358976C2 (ru) 2009-06-20
US7482356B2 (en) 2009-01-27
NO20062639L (no) 2006-06-08
KR100835152B1 (ko) 2008-06-09
PE20050578A1 (es) 2005-09-26
KR20060086391A (ko) 2006-07-31
CN1878772A (zh) 2006-12-13
US20050113392A1 (en) 2005-05-26
EP1682551A2 (en) 2006-07-26
MA28154A1 (fr) 2006-09-01
IL175151A0 (en) 2006-09-05
WO2005047287A3 (en) 2005-07-28
JP2007510739A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007038466A3 (en) Treatment of bipolar disorder utilizing anti-fungal compositions
BR112018074342A2 (pt) intensidade de disco de controle adaptativo de potência multiplexada de trilhos de potência de suprimento em um sistema de multiplexação de potência para um circuito energizado
BR0213129A (pt) Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
BRPI0519626A2 (pt) mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
BRPI0517820A (pt) composição, e, método
AP2002002426A0 (en) Ppar agonists
CR8881A (es) Compuestos heteroaril- y fenilsulfamoilo sustituidos
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
GT200500179BA (es) Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados
BR112012021337A2 (pt) formulações de apixaban.
BRPI0514474A (pt) multiparticulados
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
NO20081067L (no) Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
ECSP067070A (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR037909A1 (es) Composiciones de formulaciones para lactantes que comprenden cantidades incrementadas de alfa-lactalbumina
NO20081725L (no) Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler
CL2009001874A1 (es) Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661.
BRPI0507986A (pt) composto, composição farmacêutica, método para o tratamento de obesidade, de distúrbio obsessivo compulsivo, de depressão, e de ansiedade em mamìferos, e, uso de um composto
BRPI0515940A (pt) membro linear
ECSP099529A (es) Inhibidores de cinasa mapk/erk
HN2009000018A (es) Inhibidores de tirosina quinasa
UY29771A1 (es) Nueva forma cristalina
BRPI0516034A (pt) método de produção de uma composição
DE60228235D1 (de) Tiernahrungszusammensetzung zur verbesserung der haut

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.